Janux Therapeutics, Inc. (JANX) earnings
JANX earnings moved a median of -1.34% by the close. Quarterly and annual JANX reports and results, each read against the price at its own news timestamp. Back to the JANX overview →
21 measured JANX earnings events.
Where these JANX earnings landedvs 21 measured JANX earnings reactions
| Middle 50% of JANX earnings reactions | -3.04% to +2.27% |
|---|---|
| Median reaction (to close) | -1.34% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 JANX earnings events with a measured close landed between -3.04% and +2.27%; 48% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Janux Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.89% | +0.76% | |
| Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights | Press release | +0.89% | +0.76% | |
| Form 10-Q Janux Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -3.05% | -1.83% | |
| Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights | Press release | -3.05% | -1.83% | |
| Form 10-K Janux Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +1.07% | +0.22% | |
| Form 10-Q Janux Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.65% | -9.13% | |
| Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights | Press release | -0.65% | -9.13% | |
| Form 10-Q Janux Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +1.89% | +2.61% | |
| Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights | Press release | +1.89% | +2.61% | |
| Form 10-Q Janux Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +3.63% | -3.37% | |
| Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | Press release | +3.63% | -3.37% | |
| Form 10-K Janux Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.22% | +1.61% | |
| Form 10-Q Janux Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.19% | -3.04% | |
| Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights | Press release | -0.19% | -3.04% | |
| Form 10-Q Janux Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -3.27% | +2.27% | |
| Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights | Press release | -3.27% | +2.27% | |
| Form 10-Q Janux Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +2.70% | +3.15% | |
| Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights | Press release | +2.70% | +3.15% | |
| Form 10-K Janux Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.05% | -4.79% | |
| Form 10-Q Janux Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -4.92% | -1.34% | |
| Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights | Press release | -4.92% | -1.34% |
Keep exploring
More JANX: analyst actions → · SEC filings → · JANX overview →